Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Long-term hydroxyurea in combination with didanosine and stavudine for thetreatment of HIV-1 infection
Autore:
Rutschmann, OT; Vernazza, PL; Bucher, HC; Opravil, M; Ledergerber, B; Telenti, A; Malinverni, R; Bernasconi, E; Fagard, C; Leduc, D; Perrin, L; Hirschel, B;
Indirizzi:
Univ Hosp Geneva, Div Infect Dis, CH-1211 Geneva 14, Switzerland Univ HospGeneva Geneva Switzerland 14 s, CH-1211 Geneva 14, Switzerland Canton Hosp St Gallen, St Gallen, Switzerland Canton Hosp St Gallen St Gallen Switzerland len, St Gallen, Switzerland Univ Basel Hosp, CH-4031 Basel, Switzerland Univ Basel Hosp Basel Switzerland CH-4031 sp, CH-4031 Basel, Switzerland Univ Zurich Hosp, CH-8091 Zurich, Switzerland Univ Zurich Hosp Zurich Switzerland CH-8091 CH-8091 Zurich, Switzerland Univ Lausanne Hosp, Lausanne, Switzerland Univ Lausanne Hosp Lausanne Switzerland nne Hosp, Lausanne, Switzerland Univ Hosp Bern, CH-3010 Bern, Switzerland Univ Hosp Bern Bern Switzerland CH-3010 Bern, CH-3010 Bern, Switzerland Osped Civico Lugano, Lugano, Switzerland Osped Civico Lugano Lugano Switzerland vico Lugano, Lugano, Switzerland
Titolo Testata:
AIDS
fascicolo: 14, volume: 14, anno: 2000,
pagine: 2145 - 2151
SICI:
0269-9370(20000929)14:14<2145:LHICWD>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN-IMMUNODEFICIENCY-VIRUS; CONTROLLED TRIAL; PLUS DIDANOSINE; ANTIRETROVIRAL THERAPY; NAIVE PATIENTS; FOLLOW-UP; ZIDOVUDINE; INDIVIDUALS; LAMIVUDINE; INDINAVIR;
Keywords:
hydroxyurea; didanosine; stavudine; highly active antiretroviral therapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Hirschel, B Univ Hosp Geneva, Div Infect Dis, CH-1211 Geneva 14, Switzerland Univ Hosp Geneva Geneva Switzerland 14 eneva 14, Switzerland
Citazione:
O.T. Rutschmann et al., "Long-term hydroxyurea in combination with didanosine and stavudine for thetreatment of HIV-1 infection", AIDS, 14(14), 2000, pp. 2145-2151

Abstract

Objective and methods: In 1998 we reported on a randomized comparison between stavudine plus didanosine plus placebo versus stavudine plus didanosineplus hydroxyurea (HU), in patients with a CD4 count of 200-500 x 10(6) cells/l. After 3 months, the HU group had a higher proportion of patients withviral load < 200 x 10(6) cells/l. At the End of the 3 months blinded period, patients in the placebo group had the option to add HU if their viral load remained > 200 x 10(6) cells/l. We report results after 24 months. Results: Seventy-two patients were randomized to the HU arm, and a further30 elected to add HU after 12 weeks. Twenty-four months after the start ofthe trial, only 25% of the 72 patients originally randomized to HU, and 20% of the 30 who added HU after week 12, were still taking it. The reasons for stopping HU were: lack of efficacy (45%), adverse events (37%) and patient or physician preference (18%). Side effects were more frequent in the didanosine/stavudine/HU group than in the didanosine/stavudine group: neuropathy (35 versus 15%, P < 0.02), fatigue (22 versus 7%, P < 0.01), and nauseaor vomiting (26 versus 9%, P < 0.01). Of those who had discontinued HU, 73% were taking three drugs including a protease inhibitor. Patients who had started HU were compared with similar patients who had started protease inhibitors in the Swiss cohort. The probability of stopping HU was higher thanthe probability of stopping nelfinavir or indinavir, and similar to the probability of stopping ritonavir. Conclusion: HU increased the antiviral effect of stavudine plus didanosine. However, side effects were more frequent, and after 24 months the majority of patients had switched to protease inhibitor regimens. (C) 2000 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 10:09:48